Allist Pharmaceuticals, Inc.
New trial — A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
New trial
53/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5
New phase 2 trial NCT06008288 posted by Allist Pharmaceuticals, Inc.: "A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).
Why nowClinicalTrials.gov record updated 179 days ago.
ConfidenceHigh · 87%